Design, Synthesis and In Vitro Evaluation of Levodopa Stearic Acid Hydrazide Conjugate for the Management of Parkinson’s DiseaseNovel Conjugate for Parkinson’s Disease
Drug Research · 01.02.2024 · 74 (02) · 60-66
DOI: 10.1055/a-2234-9859 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Research, erschienen am 01.02.2024. Verfasst von Vasanthi Chinraj und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India. Hauptthemen laut MEDLINE: Parkinson Disease, Neurodegenerative Diseases, Stearic Acids. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
Parkinson’s disease is the highest prevalent neurodegenerative disease in elderly individuals after Alzheimer’s disease. The pathological identification for Parkinson’s disease is loss of dopaminergic neurons in substantia nigra region of the brain that in turn leads to dopamine deficiency that affects the body’s normal physiological and neurological disorder. The important drawback in the modality of treatment is levodopa is only supplying depleted dopamine in the brain, it does not affect neurodegeneration. Even though levodopa manages the disease, an alternative treatment strategy is required to stop or prevent further degeneration of neuron. The compound with neuroprotector activity suits the requirement. Of them, stearic acid plays a vital role in protecting neurons against oxidative stress through a Phosphoinositide 3-kinase-dependent mechanism. Hence, our present study aimed to design, synthesize, and characterize the levodopa stearic acid hydrazide conjugate. Additionally, evaluate the cytotoxicity of synthesized compound in SHSY5Y cell lines. In brief, levodopa was conjugated to the stearic acid successfully and was confirmed with Fourier-transform infrared spectroscopy, Nuclear magnetic resonance, and Mass Spectroscopy. In vitro cell viability study in SHSY5Y cell lines showed elevated cell viability in 0.134 µm concentration of Conjugate, and 0.563 µm concentration of levodopa. Showing that the synthesized compound could offer an improved treatment strategy for Parkinson’s disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India.
- Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India.
Zitieren
APA
Chinraj, V., Reddy, R. A., Selvaraj, J., & Sureshkumar, R. (2024). Design, Synthesis and In Vitro Evaluation of Levodopa Stearic Acid Hydrazide Conjugate for the Management of Parkinson’s DiseaseNovel Conjugate for Parkinson’s Disease. Drug Research, 74(02), 60-66. https://doi.org/10.1055/a-2234-9859
Vancouver
Chinraj V, Reddy RA, Selvaraj J, Sureshkumar R. Design, Synthesis and In Vitro Evaluation of Levodopa Stearic Acid Hydrazide Conjugate for the Management of Parkinson’s DiseaseNovel Conjugate for Parkinson’s Disease. Drug Research. 2024;74(02):60-66. doi:10.1055/a-2234-9859
BibTeX
@article{Chinraj2024,
author = {Chinraj, Vasanthi and Reddy, Ramakkamma Aishwarya and Selvaraj, Jubie and Sureshkumar, Raman},
title = {Design, Synthesis and In Vitro Evaluation of Levodopa Stearic Acid Hydrazide Conjugate for the Management of Parkinson’s DiseaseNovel Conjugate for Parkinson’s Disease},
journal = {Drug Research},
year = {2024},
volume = {74},
number = {02},
pages = {60--66},
doi = {10.1055/a-2234-9859}
}
EUVIMED